Effect Of Tongmai Huazhuo Decoction On Coronary Heart Disease Model Rats

Coronary atherosclerotic heart disease (hereinafter referred to as coronaryheart disease, CHD) is one of the illnesses that seriously endanger human healthand more and more gets the attention of scholars both at home and abroad.Atpresent, the pathogenesis of CHD has not been clarified, it mainly has threehypotheses which are Lipid infiltration, inflammatory reaction and endothelialcell injury. The CHD belongs to“Chest tightness”of Chinese medicine category,it has many complex clinical pattern of syndrome, which is difficult to hold.However, the vary of life style and the high pressures of society, intermin-gledphlegm and blood stasisphlegm type of syndrome becomes more and more common,sothe simultaneous treatment of phlegm and stasis is becoming a new guide andemphasis. Based on the "phlegm and blood stasis with disease" theory,theresearch on the basis of previous literature research and clinical observationconsiders that the main pathomechanism of CHD is the biding of phlegm and stasis.Based on such principle to formulate a recipe,my teater made the Vessel-unblocking and Turbid-dissolving Decoction(abbrevated as VTD) and used toclinic then received good result.So we carry out the basic research in animalexperiments for further clarify the pathogenesis of CHD, expound the targetsof Vessel-unblocking and Turbid-dissolving Decoction(abbrevated as VTD)intreating CHD, provide powerful experimental data of new drug development andclinical application.Purpose: Make observation on the effect of Vessel-unblocking andTurbid-dissolving Decoction (VTD) on the blood fat vascular endothelial andinflammatory factor in rats with coronary heart disease, and then discuss thepossible mechanism of such efficacy. Methods: Pathogen-free SD rats were selected, randomized into control group,model group, VTD high dose group, VTD middle-dose group, VTD low-dose group,and Xuezhikang group. All the rats, except those from control group, were inducedinto coronary heart disease by concomitant methods of fatty infiltration andcalcium overload. The rats from each group were fixed on the back for makingrecords by2-lead electrocardiogram (ECG). After they were successfully modeled,the rats began to receive the interventions mentioned above varying from groupto group for4weeks.After7，14and28days，at each time point rats weresacrificed to take sample.Then the levels of ApoAⅠ,ApoB100and Lp (a)were testedby ITMImmunoturbidimetry. The levels of TG, TC,LDL-C and HDL-C were tested byenzyme assay.The levels of TXB2, ET and6-keto-PGF(1α) were tested by nonequilibrium method.Later,they were sacrificed to reap the coronary artery ofeach, which was confirmed by HE staining to observe the morphological changes.The methods of RT-PCR and Western blot was adopted to determine theirmRNA-protein expressions of the cardiacApoAⅠ,ApoB, APN and TNF-αwith thedifferences being analyzed.Result:1.CHD models can be successfully induced through the methods of lipidinfiltration, calcium overload as well as intraperitoneal injection ofpituitrin;2. VTD decoction can reduce CHD rats’ level of TC,TG,LDL-C,ApoB100and Lp(a)，while increase their level of HDL-C and ApoAⅠ;3. Reduced levels of TXB2and ET and raised level of6-k-PGF(1α)can be observedin VTD treatment group;4. VTD is proved to be effective in improving or maintaining the mRNA and proteinexpression of APN and ApoAⅠ, and in decreasing and inhibiting the mRNA andprotein expression of TNF-α and ApoB.Conclusion：VTD, the recipe that is formulated under the method of simultaneous treatment of phlegm and stasis, can remove lipid plaque, Repair damaged endothelium,prevent thrombosis and relieve the MI through its regulation on lipid metabolism,so as to achieve the efficacy on CHD.